Quarterly report [Sections 13 or 15(d)]

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.26.1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
6 Months Ended
Jun. 30, 2026
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

Three-Month Periods Ended June 30, 

Six-Month Periods Ended June 30, 

($’s in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Emrosi®

$

8,074

$

2,795

$

14,326

$

4,865

Qbrexza®

5,114

6,949

10,142

12,110

Accutane®

 

3,358

 

3,395

 

6,672

 

7,050

Foam franchise products (Amzeeq® & Zilxi®)

941

1,135

1,991

2,661

Eurax®

120

120

Other / legacy

232

735

509

1,462

Total product revenues

$

17,839

$

15,009

$

33,760

$

28,148

Schedule of other revenue

Three-Month Periods Ended June 30, 

Six-Month Periods Ended June 30,

($’s in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Cutia supply agreement

$

635

$

$

635

$

Royalties on sales of Amzeeq by Cutia

36

76

Total other revenue

$

671

$

$

711

$